Clinical performance of the PreTect HPV-proofer E6/E7 mRNA assay in comparison with that of the hybrid capture 2 test for identification of women at risk of cervical cancer

Journal of Clinical Microbiology

Volumn 48, Issue 8, 2010, Pages 2779-2785

  Ratnam, Samuel ^a,b,d   Coutlee, Francois ^c   Fontaine, Dan ^d,e   Bentley, James ^f   Escott, Nicholas ^g   Ghatage, Prafull ^h   Gadag, Veeresh ^d,e   Holloway, Glen ^g   Bartellas, Elias ^d,e   Kum, Nick ^d,e   Giede, Christopher ⁱ   Lear, Adrian ^j  

^a Newfoundland and Labrador Public Health Laboratory   (Canada)

^b Public Health Laboratory   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^h TOM BAKER CANCER CENTRE   (Canada)

ⁱ ROYAL UNIVERSITY HOSPITAL   (Canada)

^j Dr H Bliss Murphy Cancer Centre   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; DNA DETERMINATION; FEMALE; GENE EXPRESSION; GENOTYPE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; WART VIRUS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVIX; VAGINA SMEAR; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVIX UTERI; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VAGINAL SMEARS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

MESSENGER RNA; ONCOPROTEIN; VIRUS DNA; VIRUS RNA;

EID: 77955451242     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00382-10     Document Type: Article

References (46)

1. Basu, P., S. Roychowdhury, U. D. Bafna, S. Chaudhury, S. Kothari, R. Sekhon, D. Saranath, S. Biswas, P. Gronn, I. Silva, M. Siddiqi, and S. Ratnam. 2009. Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac. J. Cancer Prev. 10:27-34.
2. Bosch, F. X., A. N. Burchell, M. Schiffman, A. R. Giuliano, S. de Sanjose, L. Bruni, G. Tortolero-Luna, S. Kruger Kjaer, and N. Muñoz. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26S:K1-K16.
3. Bulkmans, N. W. J., J. Berkhof, L. Rozendaal, F. J. van Kemenade, A. J. P. Boeke, S. Bulk, F. J. Voorhorst, R. H. M. Verheijen, K. van Groningen, M. E. Boon, W. Ruitinga, M. van Ballegooijen, P. J. F. Snijders, and C. J. L. M. Meijer. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772.
4. Castle, P. E., D. Solomon, C. M. Wheeler, P. E. Gravitt, S. Wacholder, and M. Schiffman. 2008. Human papillomavirus genotype specificity of Hybrid Capture 2. J. Clin. Microbiol. 46:2595-2604.
5. Clifford, G. M., J. S. Smith, T. Aguado, and S. Franceschi. 2003. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89:101-105.
6. Clifford, G. M., J. S. Smith, M. Plummer, N. Muñoz, and S. Franceschi. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88:63-73.
7. Coutlée, F., D. Rouleau, G. Ghattas, C. Hankins, S. Vézina, P. Coté, J. Macleod, A. de Pokomandy, D. Money, S. Walmsley, H. Voyer, P. Brassard, and E. Franco. 2007. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the Linear Array HPV genotyping test. J. Clin. Microbiol. 45:3821-3823.
8. Coutlée, F., D. Rouleau, P. Petignat, G. Ghattas, J. R. Kornegay, P. Schlag, S. Boyle, C. Hankins, S. Vézina, P. Coté, J. Macleod, H. Voyer, P. Forest, S. Walmsley, The Canadian Women's HIV Study Group, and E. L. Franco. 2006. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. J. Clin. Microbiol. 44:1998-2006.
9. Cuschieri, K. S., M. J. Whitley, and H. A. Cubie. 2004. Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J. Med. Virol. 73:65-70.
10. Cuzick, J., M. Arbyn, R. Sankaranarayanan, V. Tsu, G. Ronco, M. H. Mayrand, J. Dillner, and C. J. L. M. Meijer. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl. 10):K29-K41.
11. Cuzick, J., C. Clavel, K. U. Petry, C. J. L. M. Meijer, H. Hoyer, S. Ratnam, A. Szarewski, P. Birembaut, S. Kulasingam, P. Sasieni, and T. Iftner. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer. 119:1095-1101.
12. Dockter, J., A. Schroder, C. Hill, L. Guzenski, J. Monsonego, and C. Giachetti. 2009. Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J. Clin. Virol. 45:S55-S61.
13. Franceschi, S., and G. M. Clifford. 2005. Re: a study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl. Cancer Inst. 97:938-939.
14. Franco, E. L., J. Cuzick, A. Hildesheim, and S. de Sanjosé. 2006. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl. 3):S3/171-177.
15. Ginocchio, C. C., D. Barth, and F. Zhang. 2008. Comparison of the third wave invader human papillomavirus (HPV) assay and the Digene HPV Hybrid Capture 2 assay for detection of high-risk HPV DNA. J. Clin. Microbiol. 46:1641-1646.
16. Huang, S., B. Erickson, N. Tang, W. B. Mak, J. Salituro, J. Robinson, and K. Abravaya. 2009. Clinical performance of Abbott RealTime high risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J. Clin. Virol. 45:S19-S23.
17. Keegan, H., J. McInerney, L. Pilkington, P. Grønn, I. Silva, F. Karlsen, N. Bolger, C. Logan, L. Furuberg, J. O'Leary, and C. Martin. 2009. Comparison of HPV detection technologies: Hybrid capture 2, PreTect™ HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J. Virol. Methods 155:61-66.
18. Khan, M. J., P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079.
19. Koliopoulos, G., M. Arbyn, P. Martin-Hirsch, M. Kyrgiou, W. Prendiville, and E. Paraskevaidis. 2007. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol. Oncol. 104:232-246.
20. Kraus, I., T. Molden, L. E. Ernø, H. Skomedal, F. Karlsen, and B. Hagmar. 2004. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br. J. Cancer 90:1407-1413. (Pubitemid 38586270)
21. Kraus, I., T. Molden, R. Holm, A. K. Lie, F. Karlsen, G. B. Kristensen, and H. Skomedal. 2006. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J. Clin. Microbiol. 44:1310-1317.
22. Lie, A. K., and G. Kristensen. 2008. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev. Mol. Diagn. 8:405-415.
23. Lie, A. K., B. Risberg, B. Borge, B. Sandstad, J. Delabie, R. Rimala, M. Onsrud, and S. Thoresen. 2005. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol. 97:908-915.
24. Mayrand, M. H., E. Duarte-Franco, I. Rodrigues, S. D. Walter, J. Hanley, A. Ferenczy, S. Ratnam, F. Coutlée, and E. L. Franco for the Canadian Cervical Cancer Screening Trial Study Group. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588.
25. Meijer, C. J. L. M., J. Berkhof, P. E. Castle, A. T. Hesselink, E. L. Franco, G. Ronco, M. Arbyn, F. X. Bosch, J. Cuzick, J. Dillner, D. A. M. Heideman, and P. J. F. Snijders. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520.
26. Molden, T., I. Kraus, F. Karlsen, H. Skomedal, J. F. Nygård, and B. Hagmar. 2005. Comparison of human papillomavirus messenger RNA and DNA detection: a cross sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev. 14:367-372.
27. Molden, T., I. Kraus, H. Skomedal, T. Nordstrøm, and F. Karlsen. 2007. PreTect™ HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J. Virol. Methods 142:204-212. (Pubitemid 46590424)
28. Molden, T., J. F. Nygård, I. Kraus, F. Karlsen, M. Nygård, G. B. Skare, H. Skomedal, S. Ø. Thoresen, and B. Hagmar. 2005. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 114:973-976.
29. Münger, K., A. Baldwin, K. M. Edwards, H. Hayakawa, C. L. Nguyen, M. Owens, M. Grace, and K. W. Huh. 2004. Mechanisms of human papillomavirus- induced oncogenesis. J. Virol. 78:11451-11460.
30. Muñoz, N., F. X. Bosch, S. de Sanjosé, R. Herrero, X. Castellsagué, K. V. Shah, P. J. F. Snijders, and C. J. L. M. Meijer for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
31. Naucler, P., W. Ryd, S. Törnberg, A. Strand, G. Wadell, K. Elfgren, T. Rådberg, B. Strander, O. Forslund, B. G. Hansson, E. Rylander, and J. Dillner. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597.
32. Poljak, M., I. J. Marin, K. Seme, and A. Vince. 2002. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 25:S89-S97.
33. Ratnam, S., E. L. Franco, and A. Ferenczy. 2000. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev. 9:945-951.
34. Ronco, G., P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. D. Palma, A. Del Mistro, A. Gillio-Tos, D. Minucci, C. Naldoni, R. Rizzolo, P. Schincaglia, R. Volante, M. Zappa, M. Zorzi, J. Cuzick, and N. Segnan. 2008. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100:492-501.
35. Safaeian, M., R. Herrero, A. Hildesheim, W. Quint, E. Freer, L. J. van Doorn, C. Porras, S. Silva, P. González, M. C. Bratti, A. C. Rodriguez, and P. Castle for the Costa Rican Vaccine Trial Group. 2007. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J. Clin. Microbiol. 45:1447-1454.
36. Sankaranarayanan, R., B. M. Nene, S. S. Shastri, K. Jayant, R. Muwonge, A. M. Budukh, S. Hingmire, S. G. Malvi, R. Thorat, A. Kothari, R. Chinoy, R. Kelkar, S. Kane, S. Desai, V. R. Keskar, R. Rajeshwarkar, N. Panse, and K. A. Dinshaw. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385-1394.
37. Saslow, D., C. D. Runowicz, D. Solomon, A. B. Moscicki, R. A. Smith, H. J. Eyre, and C. Cohen. 2002. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52:342-362.
38. Smith, J. S., L. Lindsay, B. Hoots, J. Keys, S. Franceschi, R. Winer, and G. M. Clifford. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121:621-632.
39. Solomon, D., D. Davey, R. Kurman, A. Moriarty, D. O'Connor, M. Prey, S. Raab, M. Sherman, D. Wilbur, T. Wright, Jr., and N. Young for the Forum Group Members and Bethesda 2001 Workshop. 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287:2114-2119.
40. Sotlar, K., A. Stubner, D. Diemer, S. Menton, M. Menton, K. Dietz, D. Wallwiener, R. Kandolf, and B. Bültmann. 2004. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J. Med. Virol. 74:107-116.
41. Stoler, M. H., P. E. Castle, D. Solomon, and M. Schiffman. 2007. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am. J. Clin. Pathol. 127:335-337.
42. Szarewski, A., L. Ambroisine, L. Cadman, J. Austin, L. Ho, G. Terry, S. Liddle, R. Dina, J. McCarthy, H. Buckley, C. Bergeron, P. Soutter, D. Lyons, and J. Cuzick. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17:3033-3042.
43. van Hamont, D., M. A. P. C. van Ham, J. M. J. E. Bakkers, L. F. A. G. Massuger, and W. J. G. Melchers. 2006. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche Linear Array HPV genotyping test. J. Clin. Microbiol. 44:3122-3129.
44. Wright, T. C., L. S. Massad, C. J. Dunton, M. Spitzer, E. J. Wilkinson, and D. Solomon for the American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2007. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197:346-355.
45. Wright, T. C., L. S. Massad, C. J. Dunton, M. Spitzer, E. J. Wilkinson, and D. Solomon for the American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2007. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocercinoma in situ. Am. J. Obstet. Gynecol. 197:340-345.
46. zur Hausen, H. 1994. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr. Top. Microbiol. Immunol. 186:131-156.